Does an ‘aspirin-a-day’ keep the doctor away? by Berkel, H J
In this issue of the British Journal of Cancer, Collett et al (1999)
report on an interesting, and until now mostly missing, piece of the
jigsaw puzzle concerning the relationship between colorectal
cancer risk and the use of non-steroidal anti-inflammatory drugs
(NSAIDs).
Waddell, in 1983, was the first to report on the results of the
treatment of four patients with multiple colorectal polyps with
Sulindac, one of the drugs in the class of NSAIDs (Waddell and
Loughrey, 1983). All his patients showed a remarkable regression
and even disappearance of the polyps when given Sulindac. After
the publication of this first case-series, another nine papers
reporting on a total of 100 patients were published. It is quite
remarkable that overall a 100% response rate was found in these
100 patients. That is to say, in all the patients the polyps in the
large intestine either disappeared completely or greatly diminished
in size and number. It also has to be noted that these initial patients
treated with Sulindac were patients with polyposis related to
hereditary conditions, such as Gardner￿s syndrome or familial
polyposis coli, who had undergone a subtotal colectomy for their
underlying disease. Therefore these patients are not really compar-
able to the average patient with a sporadic adenomatous polyp.
In addition to these early clinical results, a large number of
animal-experimental studies was performed evaluating the effect
of NSAIDs on colorectal cancer in a variety of animal models.
These studies were done using different NSAIDs, under often
different circumstances and with a variety of outcome and effect
measures. Virtually all of the animal-experimental work confirms
the results of the clinical case-series: administration of NSAIDs
reduces the risk and the prevalence of indicators for colorectal
carcinogenesis.
The next question was obviously to evaluate the effect — if any —
of the use of these drugs on colorectal cancer risk in humans.
Virtually all descriptive epidemiological studies (Berkel et al,
1996) have shown an inverse relationship between use of NSAIDs
and subsequent colon cancer risk, suggesting a protective effect.
Among the epidemiological studies were cohort studies, and
case—control studies performed in different settings and among
different populations. In addition, a reduced incidence of
colorectal cancer was found in several populations who were often
prescribed these drugs for other diseases, i.e. patients with
rheumatoid disorders. All these pieces of the puzzle taken together
make for an overall picture which is very suggestive of a
cause—effect relationship. Several pieces of the puzzle were still
missing, however, and questions remained in particular with
regard to dose—response and duration of use required to have a
protective effect; in particular, since in the only reported inter-
vention study, the Physicians Health Study, no beneficial effect of
low-dose aspirin (325 mg on alternate days) on colorectal cancer
risk was observed after 5 years of follow-up (Gann et al, 1993). In
the Nurses Health Study a significant trend in protective effect
was found with longer duration of use among women who took
‡2 aspirins (Giovannucci et al, 1995). The largest risk reduction
was found in women who used aspirin consistently for > 20 years
(relative risk = 0.56).
The question of induction and latent period (￿how long does it
take before an effect is evident?￿) was eloquently addressed in the
study by Collet, reported in this issue of the journal (Collet et al,
1999). In a non-concurrent cohort linkage study, linking the popu-
lation-based cancer registry with the database of the province-
wide drug prescription plan in the province of Saskatchewan,
Canada, the investigators were able to show that it took ‡10 years
for a protective effect of NSAID use to become apparent.
Although this result seems to be consistent with the earlier results
from the Nurses Health Study, there are some questions about the
reliability of their conclusions: because of the fact that the investi-
gators used the Drug Prescription database, there is a distinct
possibility for mis-classification bias. On the one hand there is an
obvious underestimate of exposure: no data are available about
so-called ￿over the counter￿ drug use, and since aspirin is an
over the counter drug and is/has been widely available without
prescription for a large mixed group of disorders, a differential
trend in use over time could seriously impact the results. On the
other hand, being given a prescription does not necessarily mean
that the drugs are indeed used. In addition, since the investigators
choose not to evaluate — for a variety of good reasons — the effects
of individual NSAIDs, but rather use a composite measure of
overall use, it is not clear which of the NSAIDs — if any — is
preferable.
Despite the potential pitfalls of this study, it contributes signifi-
cantly to the ever growing body of research which has suggested
that NSAIDs have a protective effect on colorectal cancer develop-
ment in humans. At least three patho-physiological mechanisms
have been suggested to explain this beneficial effect. Firstly, it
appears that certain prostaglandins, in particular prostaglandin
E2, can inhibit cellular immune responses which are important in
the host defense against malignant cells. NSAIDs, through their
inhibitory effect on the cyclo-oxygenase (COX) enzymes, block
the production of prostaglandin E2 and thus may inhibit
prostaglandin-dependent immunosuppression, allowing augmen-
tation of the anti-tumour aspects of the cellular immune response.
Secondly, through its inhibitory effects on the two COX enzymes,
COX-1 and COX-2, the arachidonic acid metabolism is influ-
enced. Marnett (1992) concluded that there was overwhelming
support for the notion that influences on arachidonic acid metabo-
lism contribute to the carcinogenetic process in humans and that it
is therefore possible to modulate carcinogenesis through, for
example, the use of COX-inhibitors. Finally, recently it has been
suggested that NSAIDs may exert their protective effect through
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Article no. bjoc.1999.0641an effect on apoptosis. Apoptosis, or programmed cell death, and
the relation between cell division and cell death are believed to be
crucial in tumorigenesis. Defective regulation of apoptosis can
promote the tumour development. Several metabolites of NSAIDs
have been shown to inhibit cell cycle progression without signifi-
cantly reducing prostaglandin E2 levels, which may indicate an
effect on apoptosis. It seems unlikely that any of these mecha-
nisms in and by themselves are responsible for all of the poten-
tially beneficial effects of NSAID use, rather it can be expected
that the patho-physiological mechanisms underlying the effects of
NSAIDs are multifactorial.
One issue which the study by Collett et al (1999) did not, and
could not, address is the concern about side-effects of these drugs.
Aspirin and the other NSAIDs are well known for their side-
effects, in particular on the upper gastrointestinal tact. The most
severe of these complications is bleeding peptic ulcers. It is not
acceptable to advocate a (chemo-)preventive strategy to the popu-
lation-at-large when a high risk for major side-effects exists. In
that regard the development of more specific COX-2 inhibitors is
of great interest. These drugs, the first of which has recently been
approved by the Food and Drug Administration in the USA for use
in patients with rheumatoid arthritis, are suggested to have many
fewer gastrointestinal side-effects, while at the same time not
having lost their therapeutic/preventative benefits.
The crucial question now becomes, as the title of this editorial
indicates, does the use of NSAIDs indeed prevent colorectal
cancer, and should our patients be advised to use this drug in an
effort to prevent colorectal cancer? The proof-of-the-pudding, as
in many instances before, is in the eating. An impressive body of
evidence has been assembled suggesting a preventative effect of
NSAIDs on colorectal cancer risk, but the ultimate proof has not
yet been provided. We now need to proceed to the next logical step
in the sequence of research: the intervention study. The story of
b-carotene which showed great promise as a chemo-preventive
agent for lung cancer based on results of observational epidemio-
logical research, but was found not only not to decrease, but poten-
tially even to increase lung cancer risk, should remind all of us that
without positive results from solid randomized intervention trials,
it remains premature to already advise our patients to take ￿an
aspirin a day￿ to prevent colorectal cancer. Some of these trials are
underway already and it is prudent to await the results of these
studies before advocating the use of NSAIDs for the prevention of
colorectal cancer.
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